|
ENO1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.30049999991222E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.98044999999425E-05 |
| Normal-vs-Stage2 |
4.200100E-02 |
| Normal-vs-Stage3 |
8.03129999948915E-07 |
| Normal-vs-Stage4 |
1.97991999999481E-05 |
| Stage1-vs-Stage2 |
5.393400E-01 |
| Stage1-vs-Stage3 |
6.646200E-02 |
| Stage1-vs-Stage4 |
3.365800E-02 |
| Stage2-vs-Stage3 |
9.719500E-02 |
| Stage2-vs-Stage4 |
4.123700E-02 |
| Stage3-vs-Stage4 |
4.386000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.36069999992594E-07 |
| Normal-vs-AfricanAmerican |
8.234800E-04 |
| Normal-vs-Asian |
6.38239999999346E-05 |
| Caucasian-vs-AfricanAmerican |
4.460200E-01 |
| Caucasian-vs-Asian |
6.214000E-01 |
| AfricanAmerican-vs-Asian |
6.985200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.229499999997E-05 |
| Normal-vs-Female |
2.51230000025693E-07 |
| Male-vs-Female |
9.202800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.16529999999648E-06 |
| Normal-vs-Age(41-60Yrs) |
9.55889999999515E-05 |
| Normal-vs-Age(61-80Yrs) |
3.70980000000687E-05 |
| Normal-vs-Age(81-100Yrs) |
7.176600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.792600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.801800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.144400E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.706630E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.374400E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.270800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.399610E-01 |
| Classical-VS-Follicular |
2.755500E-03 |
| Classical-VS-Other |
8.228200E-04 |
| Classical-VS-Normal |
2.21499996122532E-09 |
| Tall-VS-Follicular |
2.703400E-03 |
| Tall-VS-Other |
1.396080E-03 |
| Tall-VS-Normal |
4.14360000000613E-05 |
| Follicular-VS-Other |
2.276200E-01 |
| Follicular-VS-Normal |
2.838200E-01 |
| Other-VS-Normal |
9.483900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.6969999999974E-05 |
| Normal-vs-N1 |
5.903700E-03 |
| N0-vs-N1 |
9.091600E-01 |
|
|
